Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...

Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory ...

Backing FDA approval was the phase III PALISADE trial in which plozasiran 25 mg slashed triglyceride levels by 80% from ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...

The FDA has approved a new type of medication to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare disease that causes extremely high triglycerides.

Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA ...

Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform. The partnership gives ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...